MA44386A - Systèmes et méthodes de prédiction de demi-vie vitréenne de conjugués d'agent thérapeutique et de polymère - Google Patents

Systèmes et méthodes de prédiction de demi-vie vitréenne de conjugués d'agent thérapeutique et de polymère

Info

Publication number
MA44386A
MA44386A MA044386A MA44386A MA44386A MA 44386 A MA44386 A MA 44386A MA 044386 A MA044386 A MA 044386A MA 44386 A MA44386 A MA 44386A MA 44386 A MA44386 A MA 44386A
Authority
MA
Morocco
Prior art keywords
vitrean
life
systems
methods
therapeutic agent
Prior art date
Application number
MA044386A
Other languages
English (en)
Inventor
Robert Kelley
Justin Scheer
Whitney Shatz
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA44386A publication Critical patent/MA44386A/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pure & Applied Mathematics (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Physics (AREA)
  • Computing Systems (AREA)
  • Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Probability & Statistics with Applications (AREA)
  • Algebra (AREA)
  • Operations Research (AREA)
  • Evolutionary Biology (AREA)
  • Software Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA044386A 2015-10-07 2016-10-05 Systèmes et méthodes de prédiction de demi-vie vitréenne de conjugués d'agent thérapeutique et de polymère MA44386A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562238393P 2015-10-07 2015-10-07

Publications (1)

Publication Number Publication Date
MA44386A true MA44386A (fr) 2019-01-23

Family

ID=57211573

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044386A MA44386A (fr) 2015-10-07 2016-10-05 Systèmes et méthodes de prédiction de demi-vie vitréenne de conjugués d'agent thérapeutique et de polymère

Country Status (7)

Country Link
US (1) US20180293360A1 (fr)
EP (1) EP3360066A1 (fr)
JP (1) JP2019501864A (fr)
CN (1) CN108369611A (fr)
HK (1) HK1259021A1 (fr)
MA (1) MA44386A (fr)
WO (1) WO2017062407A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120893A2 (fr) 2008-03-28 2009-10-01 The Regents Of The University Of California Conjugués polypeptide-polymère et procédés d’utilisation de ceux-ci
WO2017100470A1 (fr) 2015-12-09 2017-06-15 The Regents Of The University Of California Méthodes de traitement d'une maladie ou d'un trouble oculaire
IL315639A (en) 2017-03-27 2024-11-01 Regeneron Pharma Sterilization method
CN107261124B (zh) * 2017-06-09 2020-05-22 山东大学 一种新生血管生成抑制肽及其透明质酸修饰物的制备方法与应用
WO2020005767A1 (fr) * 2018-06-25 2020-01-02 The Board Of Regents Of The University Of Oklahoma Conjugués comportant des liaisons héparosane internes et d'extrémité terminale
CA3174984A1 (fr) * 2020-04-06 2021-10-14 Drive Therapeutics L.L.C. Compositions d'aptameres bispecifiques pour le traitement de troubles de la retine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161684C (fr) 1994-03-07 2010-11-09 Larry R. Wilson Conjugues de dendrimeres biactifs et (ou) cibles
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
MX2007012061A (es) * 2005-10-18 2007-12-13 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US20110064717A1 (en) 2009-08-20 2011-03-17 Ramot At Tel-Aviv University Ltd. Homing endonuclease genes and their targets
US20120282211A1 (en) 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP3165533B1 (fr) * 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Variants de chlorotoxine, conjugués et leurs procédés d'utilisation
US20140186350A1 (en) 2012-12-18 2014-07-03 Novartis Ag Compositions and methods for long acting molecules

Also Published As

Publication number Publication date
JP2019501864A (ja) 2019-01-24
WO2017062407A1 (fr) 2017-04-13
US20180293360A1 (en) 2018-10-11
EP3360066A1 (fr) 2018-08-15
HK1259021A1 (zh) 2019-11-22
CN108369611A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
EP3682830A4 (fr) Système et cathéter de cryoablation
EP2928425A4 (fr) Systèmes et procédés de chirurgie oculaire
EP3359048A4 (fr) Système acoustique de suivi orthopédique et méthodes associées
EP3328333A4 (fr) Systèmes et méthodes d'implants cornéens
EP3660575A4 (fr) Système et procédé de suivi oculaire
EP2941565A4 (fr) Systèmes et procédés pour chirurgie oculaire
EP2968853A4 (fr) Cathéter de surpression et systèmes et procédés associés
EP3349674A4 (fr) Systèmes et procédés d'espacement d'articulation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3384468A4 (fr) Systèmes et procédés de relocalisation
IL268802A (en) Plasma confinement system and methods for use
EP3358940A4 (fr) Systèmes et procédés de culture
EP2968847A4 (fr) Cathéters de translation, systèmes et leurs procédés d'utilisation
EP3371572A4 (fr) Systèmes et procédés d'imagerie optogénétique
EP3303103A4 (fr) Systèmes et procédés pour injection d'adhésif pour ensemble noeud
BR112017002511A2 (pt) sistemas e métodos de almofada terapêutica
EP2934606A4 (fr) Unités, systèmes et procédés de stérilisation
MA49715A (fr) Oligomères et conjugués d'oligomères
EP2962265A4 (fr) Systèmes et procédés d'amélioration de la maintenance de listes de problèmes associés à un patient.
EP2925260A4 (fr) Systèmes et procédés d'introduction d'une lentille intraoculaire
EP2961350A4 (fr) Implants nasaux et systèmes et procédés d'utilisation
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
EP2928424A4 (fr) Systèmes et procédés d'humidification des yeux pendant une chirurgie oculaire
IL271124A (en) Plasma confinement system and methods for use